Subscription of shares by majority shareholder in relation to the recently completed rights emission in ViroGates A/S

21.12.2023 16:25:46 CET | ViroGates | Information about majority shareholder

COMPANY ANNOUNCEMENT - No. 27-2023 – Information about majority shareholder - 21 December 2023

BIRKERØD, DENMARK - ViroGates A/S (“VIRO”), a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, today announces that the majority shareholder of the company, N. P. Louis-Hansen ApS, has subscribed for 799,075 shares in the Company as part of the recently completed rights emission, cf. company announcement no. 19-2023 from ViroGates. The shares were allocated on 19^th December 2023 and have been transferred to the permanent ISIN as of today.

N. P. Louis-Hansen ApS is the majority shareholder with post-subscription holdings of less than 25% of the share capital and more than 25% of the voting rights in ViroGates A/S.

The announcement can be found at https://www.virogates.com/investor/announcements. 

For further information, please contact:

ViroGates A/S:

CEO, Jakob Knudsen

Tel. [phone], email: [e-mail]

Certified Advisor:

Västra Hamnen Corporate Finance

Per Lönn

Tel. [phone], email: [e-mail]

About ViroGates

ViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce healthcare costs and empower clinical staff as well as to monitor health in the general population.

The company was founded in 2000. Headquartered in Denmark, ViroGates’ sales force covers Spain, France, and Benelux, while distributors serve other markets. ViroGates’ shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit www.virogates.com.

Disclosure regulation

Prospects about the future reflect ViroGates' current expectations for future events and results. The statements are by nature inherent in risks, uncertainties and other matters that are difficult to predict or out of control. The actual results may therefore differ from the expectations expressed.

Contacts

• Jakob Knudsen, CEO, [phone], [e-mail]

Attachments

• 20231221 - ViroGates comp. ann. 27.pdf

© Ritzau Denmark, source Ritzau English Regulatory Releases